[HTML][HTML] Cost-utility analysis of dabigatran and warfarin for stroke prevention among patients with nonvalvular atrial fibrillation in India
R Aghoram, SM Kumar, SR Rajasulochana… - Value in Health …, 2022 - Elsevier
Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation
M Bergh, CA Marais, H Miller-Janson… - South African Medical …, 2013 - journals.co.za
Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …
Cost‐Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation—A Real Patient Data Analysis in a Hong Kong …
AM Chang, JCS Ho, BP Yan, CM Yu, YY Lam… - Clinical …, 2013 - Wiley Online Library
Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation
Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …
Cost-effectiveness of dabigatran compared with rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China
SJ Dong, B Wu, SD Zhai, YJ Zhang, YB Chu… - Clinical Therapeutics, 2020 - Elsevier
Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …
Health care costs and utilization of Dabigatran compared with Warfarin for secondary stroke prevention in patients with nonvalvular atrial fibrillation: a retrospective …
Background: It remains unclear whether the use of new oral anticoagulants, compared with
warfarin, is economically beneficial in Asian countries. Objective: The objective of this study …
warfarin, is economically beneficial in Asian countries. Objective: The objective of this study …
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic
AK Adcock, JK Lee-Iannotti, MI Aguilar… - The …, 2012 - journals.lww.com
Background: Warfarin has provided protection against cardioembolic stroke in the setting of
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …
Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
LK Langkilde, M Bergholdt Asmussen… - Journal of Medical …, 2012 - Taylor & Francis
Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …
What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
J Jegathisawaran, A Holbrook, JM Bowen… - Journal of Population …, 2017 - europepmc.org
Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …
fibrillation (AF) has changed the clinical management of AF. To inform decision making …
Healthcare resource utilization and costs among patients with non-valvular atrial fibrillation using dabigatran or warfarin for stroke prevention
AC Fu, R Jain, SD Sander, J Lim, G Jain… - … Quality and Outcomes, 2014 - Am Heart Assoc
Background: Dabigatran was the first novel oral anticoagulant (OAC) approved in the US for
stroke risk reduction in patients with non-valvular atrial fibrillation (NVAF). The aim of this …
stroke risk reduction in patients with non-valvular atrial fibrillation (NVAF). The aim of this …
相关搜索
- atrial fibrillation stroke prevention
- atrial fibrillation cost effectiveness
- cost effectiveness stroke prevention
- atrial fibrillation systemic embolism
- prevention of stroke systemic embolism
- dabigatran and warfarin cost utility
- atrial fibrillation dabigatran and rivaroxaban
- cost effectiveness dabigatran and rivaroxaban
- dabigatran and warfarin stroke prevention
- atrial fibrillation economic appraisal
- economic appraisal stroke prevention
- clinical practice stroke prevention
- cost utility stroke prevention
- atrial fibrillation dabigatran etexilate
- prevention of stroke dabigatran etexilate
- dabigatran and rivaroxaban stroke prevention